Mathieu Charvériat holds degrees from the École Polytechnique and Mines ParisTech, as well as a PhD in neurosciences and cell biology from the Université Pierre and Marie Curie. He joined the neurosciences research laboratory of the French Alternative Energies and Atomic Energy Commission (CEA) in 2009, working on prion diseases and non-neuronal cells, where together they published various papers and filed several patents related to the modulation of drugs targeting neurons. In March 2013, he co-founded Theranexus with Franck Mouthon. As part of his duties as Chief Scientific Officer, Mathieu Charvériat is responsible for the company's research teams and scientific partnerships.